Advertisement
U.S. Markets closed

PixarBio Corporation (PXRB)

Other OTC - Other OTC Delayed Price. Currency in USD
0.00000.0000 (0.00%)
At close: 03:17PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0000
Open0.0000
BidN/A x N/A
AskN/A x N/A
Day's Range0.0000 - 0.0000
52 Week Range0.0000 - 0.0000
Volume100
Avg. Volume100
Market Cap81
Beta (5Y Monthly)-54.43
PE Ratio (TTM)N/A
EPS (TTM)-0.1890
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for PXRB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • PIXARBIO CORP
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Rating
    Fair Value
    Economic Moat
    8 months agoMorningstar
View more
  • We're sorry we weren't able to find anything about this topic.